Disclaimer for the US market

The products and information provided on this website are intended for healthcare professionals. These products are not for sale or distribution in the United States and statements made regarding these products have not been evaluated by the U.S. Food and Drug Administration (FDA). The efficacy of these products has not been confirmed by FDA-approved research and these products are therefore not intended to diagnose, treat, cure or prevent any disease. All information presented here is for general information purposes only and not meant as a substitute for or alternative to advice from healthcare practitioners. The Federal Food, Drug and Cosmetic Act requires this notice.

Neither the Company nor its representatives is providing any medical advice, and none should be inferred, from any ideas, suggestions, testimonials or other information set forth on this website or in other Company materials or provided over the phone, in the mail, in product packaging, or in email correspondence. This website may contain links to third-party websites. The Company provides these links as a convenience only and does not endorse any of these sites. The Company is not responsible for the content of, and does not make any representations regarding the materials on, such linked third-party websites. If you decide to access or rely on information at linked third-party website, you do so at our own risk. Our terms and conditions, including disclaimers, are more fully set forth in our Terms of Use, Privacy Policy and Terms of Online Sales.

One year of clinical experience at CARL. Recap – Focus Meeting Heart in Münster

During the lunch symposium “CARL. Recap – Latest clinical experience reports and results from one year of CARL” at this year’s Focus Meeting Heart from 4 to 6 November in Münster, more than 75 participants were informed about the latest clinical application experiences for controlled whole-body reperfusion. 

Dirk Buchwald from the Bergmannsheil University Hospital in Bochum used simulations to present the use of “CARL under reanimation – the details make the difference” and demonstrated the clinical relevance in everyday clinical practice. Maik Foltan from the University Hospital Regensburg explained the possibilities and limitations of use on the basis of patient cases, with special reference to the fixation of cannulas in the context of ECPR or CARL Treatment. Finally, Jan-Steffen Pooth from the Medical Center – University of Freiburg presented the latest clinical results from the ongoing multi centre study on CARL. 

As part of the congress programme, a practical hands-on workshop was also held, in which Christian Scherer, Head of the CARL Support Team, demonstrated the commissioning of the complete CARL System in a resuscitation case. “Especially with the users of the CARL System, we see the intuitive control from expert hands in a very short time, which demonstrates the practicality”, says Thomas Kraft, CEO of Resuscitec GmbH. 

Under this year’s motto “Team Perfusion 2022 – stay connected”, the conference presidents Thomas Dreizler and Prof. Stephan Ensminger emphasised the aspect of interdisciplinary cooperation between cardiotechnology, cardiac surgery and anaesthesia as a key factor in patient care. This also applies to the CARL Concept, which was presented for the second time to more than 500 congress visitors at the International Annual Meeting of the German Society for Cardiovascular Engineering (DGfK) and the Joint Focus Meeting Heart of the German Society for Thoracic, Cardiac and Vascular Surgery (DGTHG).

< Zurück